mash wegovy - Search News

Order byBest matchMost fresh

News

Novo, Wegovy and MASH

Fierce Pharma · 3h

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Continue reading

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

· 1h · on MSN

Wegovy News Pushes Novo Nordisk Stock Higher

33m

A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

MPR37m

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Zacks Investment Research on MSN2h

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results